News | May 29, 2024
IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Subscribe To Our Newsletter & Stay Updated
